Long-Acting Injectables: LAI Antipsychotics and Extended-Release Naltrexone
A review of the FDA-approved indications and the use of long-acting injectable (LAI) antipsychotics and extended-release naltrexone in the appropriate patient populations. Mechanism of action, dosing, need for oral medication overlap, and potential adverse effects will be explored. Participants will compare and contrast the different long-acting injectable antipsychotics and identify which agent(s) may be most appropriate based on patient and product characteristics. Participants will identify patients who may benefit from extended-release naltrexone and when initiation of extended-release naltrexone is appropriate. Finally, participants will be able to list advantages and disadvantages to the use of long-acting injectable antipsychotics and extended-release naltrexone to identify possible motivations for patient acceptance of these agents.
6:00 Welcome & program
7:00 Town Hall
- List recent changes to the MN Pharmacy Act regarding pharmacist administration of medications for alcohol/opioid use disorder and mental illness
- Review the FDA-approved indications, mechanisms of action, pharmacokinetics, adverse effects, and possible advantages in the use of long-acting injectable (LAI) antipsychotic agents and extended-release naltrexone
- Compare LAI antipsychotics with regard to: site of injection, storage considerations, preparation for administration, need for loading doses, and volume to be injected
Amie Jo Digatono, PharmD, BCPP
Amie Jo Digatono, PharmD, graduated from the University of Minnesota College of Pharmacy in 2011. She is a Board-Certified Psychiatric Pharmacist with experience treating patients with severe and persistent mental illness in a state behavioral health hospital and in a community hospital inpatient unit. Her experience also includes caring for patients with substance use disorders as well as dual diagnosis patients (those with co-occurring behavioral health and substance use disorders). She enjoys volunteering at the University of Minnesota College of Pharmacy, serving as a peer reviewer for the College of Psychiatric and Neurologic Pharmacists, and working as an election judge with the city of Minneapolis. Dr. Digatono lives in Northeast Minneapolis where she herds two free-spirited tomcats and tends to an unruly native wildflower garden.
Julie Jackman, PharmD, BC-ACP
Julie Jackman is a doctor of pharmacy and Board Certified in Ambulatory Care. A 1999 graduate of the University of Pittsburgh, she has been practicing in mental health since 2008. Dr. Jackman as a holistic view when treating her patients, thanks to previous experience in community pharmacy, with additional training in diabetes and immunizations. Mental Health can impede a patient’s ability to care for themselves. Dr. Jackman strives to ensure her patient’s don’t fall through the cracks. Her unique practice was recognized in Pharmacy Today, a national pharmacy magazine, in 2009. Also in 2009, she was named Minnesota’s Distinguished Young Pharmacist. She was one of the original 512 pharmacists in the United States to earn the Board Certified Ambulatory Care Pharmacist (BC-ACP) designation in 2011. In 2014, she received the Individual Immunization Champion Award from the American Pharmacist Association (APhA) for her work in helping increase vaccination rates in the mental health population. She was also awarded the Excellence in Innovation Award from Minnesota Pharmacist’s Association in September 2014 for her work with mental health patients thru MTM. In order to advocate for her patients, she is an active member of both the Minnesota Pharmacists Association (MPhA) and the American Pharmacist Association (APhA).